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Abstract
Adenine phosphoribosyltransferase deficiency is a rare, autosomal recessive disorder of purine metabolism that causes
nephrolithiasis and progressive chronic kidney disease. The small number of reported cases indicates an extremely low
prevalence, although it has been suggested that missed diagnoses may play a role. We assessed the prevalence of APRT
deficiency based on the frequency of causally-related APRT sequence variants in a diverse set of large genomic
databases. A thorough search was carried out for all APRT variants that have been confirmed as pathogenic under
recessive mode of inheritance, and the frequency of the identified variants examined in six population genomic
databases: the deCODE genetics database, the UK Biobank, the 100,000 Genomes Project, the Genome Aggregation
Database, the Human Genetic Variation Database and the Korean Variant Archive. The estimated frequency of
homozygous genotypes was calculated using the Hardy-Weinberg equation. Sixty-two pathogenic APRT variants were
identified, including six novel variants. Most common were the missense variants c.407T>C (p.(Met136Thr)) in Japan
and c.194A>T (p.(Asp65Val)) in Iceland, as well as the splice-site variant c.400+ 2dup (p.(Ala108Glufs*3)) in the
European population. Twenty-nine variants were detected in at least one of the six genomic databases. The highest
cumulative minor allele frequency (cMAF) of pathogenic variants outside of Japan and Iceland was observed in the Irish
population (0.2%), though no APRT deficiency cases have been reported in Ireland. The large number of cases in Japan
and Iceland is consistent with a founder effect in these populations. There is no evidence for widespread underdiagnosis
based on the current analysis.
Introduction
Adenine phosphoribosyltransferase (APRT) deficiency
(OMIM 102600; 614723) is a rare disorder of purine
metabolism that is inherited in an autosomal recessive
manner [1]. In the absence of functional APRT activity,
adenine is oxidized to 2,8-dihydroxyadenine (DHA) by
xanthine oxidoreductase (xanthine dehydrogenase/oxi-
dase). Poor solubility of DHA in the urine leads to stone
formation and crystal nephropathy. Radiolucent kidney
stones are the most common clinical manifestation,
* Runolfur Palsson
runolfur@landspitali.is
1 Faculty of Medicine, School of Health Sciences, University of
Iceland, Reykjavik, Iceland
2 Internal Medicine and Rehabilitation Services, Landspitali—The
National University Hospital, Reykjavik, Iceland
3 Renal Unit, Newcastle upon Tyne Hospitals NHS Foundation
Trust, Newcastle upon Tyne, UK
4 Institute of Genetic Medicine, Newcastle University, Central
Parkway Newcastle, Newcastle upon Tyne, UK
5 NIHR Biomedical Research Centre, Newcastle upon Tyne, UK
6 Children’s Medical Center, Landspitali—The National University
Hospital, Reykjavik, Iceland
7 deCODE genetics, Reykjavik, Iceland
8 School of Engineering and Natural Sciences, University of
Iceland, Reykjavik, Iceland
Supplementary information The online version of this article (https://
doi.org/10.1038/s41431-020-00805-6) contains supplementary















followed by chronic kidney disease which has already
progressed to end-stage kidney disease in 15–20% of
patients at the time of diagnosis of APRT deficiency [2].
In some cases, the disorder is first recognized in the
setting of disease recurrence following kidney transplan-
tation. Treatment with the xanthine oxidoreductase
inhibitors allopurinol and febuxostat reduces DHA
synthesis and excretion, alleviating stone burden and
kidney injury [1].
The human APRT gene, located on chromosome 16q24,
is 2466 base pairs long and contains five exons encoding a
180 amino acid protein (NP_000476.1) [3]. The Human
Gene Mutation Database (HGMD) lists 51 reported
disease-causing variants to date. More than 300 cases
have been reported worldwide, the majority of patients
coming from Japan, France and Iceland [1]. The most
commonly reported variants are a missense variant in
exon 3, c.407T>C (p.(Met136Thr)), in patients from
Japan [4, 5], a T insertion at the splice donor site of intron
4, c.400+ 2dup (p.(Ala108Glufs*3)), among Europeans
[6, 7], and another missense variant in exon 3, c.194A>T
(p.(Asp65Val)), which accounts for all known cases of
APRT deficiency in Iceland [8, 9]. Individuals homo-
zygous for disease-causing variants have invariably been
shown to have completely abolished enzyme activity,
while heterozygous carriers have partial enzyme function
but do not appear to have any biochemical or clinical
abnormalities [10].
Although the small number of reported cases worldwide
indicates that APRT deficiency is an extremely rare con-
dition, the large number of patients identified in Japan,
France and Iceland has raised concerns that the prevalence
may be underestimated in many populations. Furthermore,
the commonly reported occurrence of delayed or missed
diagnosis suggests that lack of awareness among clinicians
might contribute to the low number of reported cases
[1, 10, 11]. However, a founder effect is a likely expla-
nation for the high frequency of a single pathogenic var-
iant and disease prevalence in the Icelandic [9, 12] and
Japanese populations [5, 13].
As whole-genome and whole-exome sequencing have
become more widely available, studies on the molecular
basis of rare diseases using open-access population-based
data have provided further insight into their pathogenesis
and allele frequency [14–16]. The aim of this study was to
search for all APRT variants confirmed as disease-causing
under recessive mode of inheritance that have been
reported in the literature and registered in online disease
databases to date, and assess the frequency of these
variants in a set of large population genomic databases
containing information on individuals from diverse geo-
graphic locations and ethnic groups.
Methods
Ethical considerations
The study was approved by the National Bioethics Com-
mittee of Iceland (NBC 09-072) and the Icelandic Data
Protection Authority.
Search for known pathogenic APRT sequence
variants
In order to identify all sequence variants documented
to cause APRT deficiency, we performed a search strategy
using three major sources through February 2020:
(1) Medical literature and databases. We performed
a web-based search and assessement of APRT
variants in reported cases of APRT deficiency
using PubMed, HGMD [17], OMIM [18], and
ClinVar [19].
(2) Expanded web sources. To search for APRT variants,
we also assessed the full text of published articles,
conference abstracts and book chapters identified using
PubMed® (https://pubmed.ncbi.nlm.nih.gov/) and Goo-
gle® (http://www.google.com), with the terms “APRT
deficiency”, “adenine phosphoribosyltransferase defi-
ciency”, “2,8-dihydroxyadenine”, “2,8-dihydroxyadeni-
nuria” and “2,8-DHA”.
(3) APRT Deficiency Registry of the Rare Kidney Stone
Consortium (RKSC; http://www.rarekidneystones.
org). Information on APRT variants was obtained
from the APRT Deficiency Registry and through
personal communication to the research group. The
RKSC was established in 2009 to study hereditary
kidney stone disorders and has since maintained a
private database with clinical information on parti-
cipating individuals. As of September 2019, 63
patients from eight countries were enrolled in the
APRT Deficiency Registry, 56 of whom had under-
gone genetic testing with the identification of
biallelic disease-causing APRT variants.
The variants are reported using nomenclature recommended
by the Human Genome Variation Society, including reference
sequence numbers (NM_000485.2 and NG_008013.1) and
transcript number (ENST00000426324.6).
As consequence at the RNA level has not been reported
for the vast majority of the variants, a prediction analysis
of the variant effect at the splice junction on the splicing
was carried out using consensus sequence frequencies,
maximum entropy modeling and the varSEAK Online
splice prediction tool (https://varseak.bio/).
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Search for known pathogenic APRT variants in
genomic databases
We looked for the pathogenic variants, identified using the
search strategy described above, in public whole-genome
and whole-exome databases through February 2020. The
individual and cumulative frequency of these disease-
causing variants was determined.
We used six databases in all, containing information on
sequence variation for over 300,000 individuals from var-
ious geographic locations and ethnic groups:
(1) The database at deCODE genetics [20] comprises
whole-genome sequencing data obtained from 53,964
Icelanders, 3153 Swedes, 8831 Danes, 2920 Norwe-
gians and 1365 Irish persons enrolled in various
studies.
(2) The UK Biobank Project [21], a large prospective
cohort study, includes exome sequencing data on
approximately 50,000 individuals (by 2019).
(3) The 100,000 Genomes Project [22] contains data on
whole-genome sequencing of 63,737 patients with
rare diseases from across the UK.
(4) The Genome Aggregation Database (gnomAD) [23]
browser (version 2.1.1) includes whole-genome and
whole-exome sequencing data on 141,456 unrelated
individuals sequenced as a part of various disease-
specific and population genetic studies of diverse
countries and ethnicities. The database includes
whole-exome sequencing of 8128 Africans and
African-Americans, 17,296 Latinos, 5040 Ashkenazi
Jews, 9197 East Asians, 10,824 Finnish and 56,885
non-Finnish Europeans, 15,308 South Asians and
3070 individuals classified as “Other“.
(5) The Human Genetic Variation Database of Japan
[24, 25] comprises exome sequencing data on 1208
individuals and genotyping information for common
variations from 3248.
(6) The Korean Variant Archive (KOVA) [26] includes
exome sequencing data on 1055 healthy Korean
individuals.
The minor allele frequency (MAF) of each causally-
related sequence variant among different ancestries was
exctracted.
Determination of cumulative allele frequency of
known pathogenic APRT variants and estimation of
homozygous genotype frequency
To determine the cumulative minor allele frequency (cMAF)
of the reported APRT variants, we used the sum of the allele
frequency of individual variants in databases of genome and
exome sequences available for a given geographic area or
ethnic group. We note that each of the individual variants is
rare and none are reported to be present on the same hap-
lotype. As APRT deficiency is an autosomal recessive dis-
ease, each affected individual is expected to carry two copies
of a disease-causing variant, either the same (homozygous)
or different variants (compound heterozygous). The Hardy-
Weinberg equation (p2+ 2pq+ q2= 1) was used to calcu-
late the expected genotype frequencies for heterozygous
(2pq) and homozygous (p2) genotypes, using the minor and
total allele counts, where p is equal to the cMAF of causally-
related variants and q is (1− p).
Results
Pathogenic APRT variants
Using a comprehensive search strategy, 62 pathogenic
variants in the APRT gene were identified in homozygous or
compound heterozygous patients with APRT deficiency
(Supplementary Tables S1 and S2). All 62 variants were
present in patients with clinical findings characteristic of
APRT deficiency and/or abolished APRT enzyme function
(94% of variants). In total, 482 cases of APRT deficiency
from 33 countries have been reported worldwide, of which
311 (64.5%) have received a molecular diagnosis to the best
of our knowledge. Thirty-seven variants were each detected
in a single affected individual. The remaining 25 variants
were observed in two or more cases, including ten which
were found in at least five individuals. There were 28
missense variants and the remaining 35 were nonsense,
insertion or deletion, frameshift and start loss, and splice
variants. Of nine presumed splice variants, six were pre-
dicted to have a splicing effect and one a likely splicing
effect (Supplementary Table S3).
We also noted two sequence variants that we do not
classify as pathogenic, each of which were reported in a
single heterozygous individual with partial APRT enzyme
deficiency; a missense variant, c.266G>A (p.(Arg89Gln)),
from Australia and the c.346G>A (p.(Ala116Thr)) missense
variant from China. These variants were quite common in
the databases searched; in gnomAD, the p.(Ala116Thr)
variant had an allele frequency of 0.23% (46/19,942) in the
East Asian population and p.(Arg89Gln) an allele frequency
of 0.41% (125/30,584) in the South Asian population.
However, neither of the two variants have been observed in
confirmed cases of APRT deficiency and, thus, were not
included in our set of 62 causally-related variants.
Of the 62 pathogenic APRT variants, 56 had already been
reported in the literature. The missense variants c.407T>C
(p.(Met136Thr)) and c.194A>T (p.(Asp65Val)) and the
splice-site variant c.400+ 2dup (p.(Ala108Glufs*3)) were
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most commonly reported. Additionally, six novel patho-
genic variants were discovered through our APRT Defi-
ciency Research Program. A C-to-G substitution in intron 1
(c.81-3C>G) was identified in the homozygous state in two
affected siblings in the US and one patient in Italy, and a
C-to-T substitution in exon 1 (c.58C>T; p.(Pro20Ser)) was
detected in a homozygous patient in the UK. Two com-
pound heterozygous patients from the US had novel
sequence variants; one of these patients had a frameshift
variant in exon 1, c.23dup (p.(Val9Glyfs*2)), and a
deletion in exon 5, c.522_524del (p.(Ser175del)), while
the other had a missense variant in exon 3, c.264G>T
(p.(Lys88Asn)), in addition to a variant that had already
been reported. The sixth variant was identified in a patient
from India who was referred to our program but had already
been found to be a compound heterozygote when evaluated
in his home institution, carrying a missense variant in exon
3, c.227C>T (p.(Ala76Val)), in addition to one previously
reported variant.
The three most common pathogenic APRT variants
All cases harboring the three most common variants causing
APRT deficiency in a homozygous or compound hetero-
zygous state are presented in Table 1. For these three var-
iants, we summarized the counts of reported cases and the
frequencies of these variants in different geographic loca-
tions and ethnic groups represented in the large population
genomic databases. These three variants were observed in
368 (63.8%) of the 576 of causally-related alleles detected
in the APRT deficiency cases.
The missense variant, c.407T>C (p.(Met136Thr))
The T-to-C missense variant at codon 136 in exon 5,
p.(Met136Thr), has been described in 134 patients of
Japanese descent, all but one of whom were previously
reported in the literature. The additional case, identified in
the APRT Deficiency Registry, was a Japanese patient
living in the US. This pathogenic variant was also found in
the Human Genetic Variation Database in Japanese cohorts
from Tohoku University (MAF 1.3%, Alt/Ref 1/76) and the
University of Tokyo (MAF 0.3%, Alt/Ref 2/666).
This geographic distribution is consistent with previous
reports [13]. In KOVA, the MAF of this variant was 0.05%
(1/1898). The variant was not detected in other genomic
databases. We note that the number of Japanese in the
gnomAD database is very low, only 150.
The missense variant, c.194A>T (p.(Asp65Val))
Forty-one cases of APRT deficiency carrying the
p.(Asp65Val) variant have been reported. Of these, 37
individuals are from Iceland, all of whom are homo-
zygous. One patient from Spain and one from the UK
were homozygous for the same variant and two other
patients were compound heterozygotes, one from France
and one from Australia. On whole-genome sequencing of
53,964 Icelanders in the deCODE database, we observed
this APRT variant in 1299 alleles, yielding a minor allele
frequency (MAF) of 1.2% (1299/107,928). Icelanders
have ancestries originating from Scandinavia and the
British Islands. Out of 14,904 whole-genome sequenced
Scandinavian individuals at deCODE, only two hetero-
zygotes carrying the p.(Asp65Val) variant were detected,
and one single heterozygote was identified in the UK
(Supplementary Table S4).
The splice-site variant, c.400+ 2dup (p.(Ala108Glufs*3))
The c.400+ 2dup variant was found in a total of 41 cases that
all are of European descent. This variant has been identified
in 13 homozygotes and 23 compound heterozygotes
from Europe, including France (n= 29), Germany, Austria,
Belgium, Italy and Poland. The variant has also been found in
patients in the US (n= 6) and Australia (n= 1). The variant
was consistently present in European populations in the
genomic databases (Supplementary Tables S4–S6). The
highest frequency was observed among Irish (MAF 0.18%;
5/2730) and Southern European (MAF 0.043%; 5/11,592)
individuals.
Allele frequency of the pathogenic APRT variants in
population databases
We searched for the presence and assessed the frequency of
the 62 pathogenic APRT variants within the publicly available
databases, by geographic location and ethnicity. Out of the 62
variants, we observed 29 in the population databases.
Two of the three most common variants described above,
p.(Met136Thr) and p.(Asp65Val), are clearly indicative of a
founder effect in Japan and Iceland, respectively, with very
low frequency in the public databases. The third variant,
c.400+ 2dup, shows a wide distribution among cases from
multiple European countries and the US, and is the disease-
causing variant with the highest occurence in public data-
bases. Besides these three variants, the most commonly
reported ones were c.294G>A (p.(Trp98*)) in 26 Japanese
cases and the c.521_523del (p.(Phe174del)) variant which
was observed in six cases from European countries and
three in the US.
Iceland is the country where the highest proportion of the
population has been sequenced (around one in six Ice-
landers). In addition to the p.(Asp65Val) variant, we dis-
covered five individuals heterozygous for one of the two
other known pathogenic APRT variants in the deCODE
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Table 1 The frequency of the three most common pathogenic APRT variants among all identified cases worldwide and in population genomic
databases.
Identified cases Genomic databases
Homozygotes Compound
heterozygotes




Japan (HGVD) 3 2326 0.13
USA 1
Korea (KOVA) 1 1898 0.05
gnomAD
African 0 16,760 0.000
Ashkenazi Jewish 0 9956 0.000
East Asian 1 18,360 0.005447
European (Finnish) 0 20,398 0.000
European (Non-Finnish) 0 112,090 0.000
Latino 0 34,518 0.000
Other 0 6066 0.000
South Asian 0 30,590 0.000
c.194A>T (p.(Asp65Val))
Iceland 37
Iceland (deCODE) 1299 107,928 1.2
Sweden (deCODE) 1 6306 0.016









African 0 24,072 0.000
Ashkenazi Jewish 0 10,156 0.000
East Asian 0 19,736 0.000
European (Finnish) 0 24,188 0.000
European (Non-Finnish) 1 124,598 0.0008026
Estonian 1 4768 0.02097
Latino 0 35,102 0.000
Other 0 7032 0.000
South Asian 0 30,262 0.000
c.400+ 2dup (p.(Ala108Glufs*3))
Europe 13 23




Ireland (deCODE) 5 2730 0.18315018
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database (Table 2). Of these, the c.1A>C (p.(Met1?)) non-
sense variant, previously reported in patients from Hungary
and France, was observed in four Icelanders with a MAF of
0.004% (4/107,928).
Estimation of homozygous APRT genotype
frequency
Based on the Hardy-Weinberg principle, the cMAF of
p.(Asp65Val) in the Icelandic population was 1.2%, with a
predicted frequency of homozygous individuals of 1 in 6840
(Table 3). In the Scandinavian countries (Denmark,
Norway and Sweden), the cumulative allele frequency of any
of the pathogenic variants in 14,904 individuals was similar
among the three nations, or around 0.05%. This would cor-
respond to an expected number of homozygotes of about one
in four million individuals, or five cases in a total population
of 20 million people. We note that no cases of APRT defi-
ciency have been reported in these three countries. In Ireland,
the cMAF of the pathogenic variants observed was 0.26%
(7/2730 alleles), represented by five copies of c.400+ 2dup
and a single copy of two other disease-causing variants. The
expected frequency of Irish individuals homozygous for a
pathogenic variant is 1 in 152,100, corresponding to roughly
30 homozygous subjects given the size of the Irish nation.
The overall frequency of the reported pathogenic variants
in gnomAD was similar among the European (non-Finnish)
population, with a calculated allele frequency of 0.05%
(63/128,838). Frequencies of causally-related variants in
Latinos and East Asians was similar to that observed
in gnomAD for Europeans, whereas other groups had
lower frequencies. Thus, there could be as many as 300
cases in the East Asian population (1.7 billion) and up to
170 cases in the Latin American population (642 million).
Discussion
A comprehensive search for APRT deficiency cases, using
multiple web-based resources and the APRT Deficiency
Registry, identified 62 pathogenic APRT variants in a total
of 311 patients undergoing molecular diagnosis. Six novel
variants were discovered through the APRT Deficiency
Registry. Three variants are by far most common among
the APRT deficiency cases, namely the missense variants
p.(Met136Thr) and p.(Asp65Val) and the splice variant
c.400+ 2dup, collectively accounting for 64% of the
disease-associated alleles.
Twenty-nine of the 62 pathogenic variants were detected
in large population genomic databases and were assessed
for the individual and cumulative frequencies. Evaluation
of the frequency of the Icelandic missense variant
p.(Asp65Val) in large datasets from ancestral populations in
Scandinavia and UK revealed that the variant is approxi-
mately 100 times less common in these geographic loca-
tions. Thus, the high carrier rate of the variant of 1.2% in
the Icelandic population clearly represents a founder effect.
Not surprisingly, analysis of the large Icelandic genomic
data disclosed a number of additional undiagnosed homo-
zygous individuals.
The high frequency of the missense variant p.(Met136Thr)
in the Japanese population is also consistent with a
Table 1 (continued)
Identified cases Genomic databases
Homozygotes Compound
heterozygotes
Allele count Allele number Allele
frequency (%)
gnomAD
African 1 24,940 0.004010
Ashkenazi Jewish 0 10,350 0.000
East Asian 0 19,942 0.000
European (Finnish) 0 24,890 0.000
European (Non-Finnish) 27 128,838 0.02096




North-West European 11 50,708 0.02169
Swedish 1 26,100 0.003831
Latino 1 35,430 0.002822
Other 0 7280 0.000
South Asian 1 30,614 0.003266
gnomAD Genome Aggregation Database, HGVD Human Genome Variation Database, KOVA Korean Variant Archive.
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founder effect. A previous study assessing the frequency of
p.(Met136Thr) observed an allele frequency of 0.13%
(3/2326) among Japanese and 0.05% (1/1898) among
Koreans, while this variant was absent in samples from Tai-
wanese individuals. In the same study, the geographic dis-
tribution in Japan was determined to be rather uniform [13].
Table 2 Pathogenic APRT variants detected in the deCODE genetics database.
No. Position (Build 38) Location Base change Amino acid change Variant type Alt/Ref MAF (%) Country of origin
1 16:88810550 Exon 3 c.194A>T p.(Asp65Val) Missense 1299/107928 1.2 Iceland
2 16:88811899 Exon 1 c.1A>C p.(Met1?) Nonsense 4/107928 0.003706 Iceland
3 16:88810141 Exon 4 c.329T>C p.(Leu110Pro) Missense 1/107928 0.000927 Iceland
4 16:88810141 Exon 4 c.329T>C p.(Leu110Pro) Missense 5/17662 0.028309 Denmark
5 16:88810067 Intron 4 c.400+2dup p.(Ala108Glufs*3) Indel 4/17662 0.02264749 Denmark
6 16:88811899 Exon 1 c.1A>C p.(Met1?) Nonsense 2/17662 0.01132374 Denmark
7 16:88810550 Exon 3 c.194A>T p.(Asp65Val) Missense 1/17662 0.00566187 Denmark
8 16:88811899 Exon 1 c.1A>C p.(Met1?) Nonsense 1/6306 0.015857913 Sweden
9 16:88810550 Exon 3 c.194A>T p.(Asp65Val) Missense 1/6306 0.015857913 Sweden
10 16:88809717 Exon 5 c.521_523del p.(Phe174del) Deletion 1/6306 0.015857913 Sweden
11 16:88810067 Intron 4 c.400+ 2dup p.(Ala108Glufs*3) Indel 5/2730 0.18315018 Ireland
12 16:88809700 Exon 5 c.541T>C p.(*181Argext*?) Stop lost 2/2730 0.07326007 Ireland
13 16:88810494 Exon 3 c.250G>A p.(Val84Met) Missense 2/5840 0.0342465 Norway
14 16:88809717 Exon 5 c.521_523del p.(Phe174del) Deletion 1/5840 0.0171232876 Norway
Reference sequence: NG_008013.1 (NM_000485.2).
Alt/ref alternate/reference alleles, Indel insertion or deletion, MAF minor allele frequency.
Table 3 Cumulative allele
count, allele frequency and
expected homozgous frequency
of pathogenic APRT variants











African 9/24,940 0.0360 7,679,057 1386
Ashkenazi Jewish 1/10,350 0.0097
East Asian 9/19,946 0.0451 4,911,641 1109
European (Finnish) 1/24,920 0.0080
European (Non-
Finnish)
63/128,828 0.0489 4,181,571 1023
Latino 11/35,430 0.0508 3,712,044 964











Denmark 12/17,662 0.0678 2,166,293 736
Sweden 3/6306 0.0476 4,418,404 1052
Norway 3/5840 0.0514 3,789,511 974
Ireland 7/2730 0.18315 298,116 274
HGVD 3/2326 0.1289 601,142 388
KOVA 1/1898 0.052687 3,602,404 950
gnomAD Genome Aggregation Database, HGVD Human Genome Variation Database, KOVA Korean
Variant Archive.
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The c.400+ 2dup variant was observed in cases from
many countries in Europe, the US and Australia, as well as
in most of the public databases used in the current study. In
a report of a French APRT deficiency cohort, this variant
was found in 54% of the patient population, all of whom
originated from metropolitan France except for one Italian
family [27]. The allele frequency of the c.400+ 2dup var-
iant was 40% in the case series. The same group of inves-
tigators also detected an allele frequency of 0.98% (2/204)
by newborn screening [27].
When calculating the cMAF of reported causally-related
variants to assess the expected genotypic frequency, we
found that there may be as many as 200 individuals in Japan
homozygous for p.(Met136Thr) and 50 in Iceland homo-
zygous for p.(Asp65Val). As expected, the two described
founder variants in Japan and Iceland are very rare outside
of their respective countries. In the European (non-Finnish)
population, the cMAF of any pathogenic variant was
0.05%. The cMAF in the Irish population was higher and is
consistent with approximately 30 homozygous individuals.
Interestingly, no cases have been diagnosed in Ireland to the
best of our knowledge, indicating that the disease may be
underreported or underdiagnosed.
Two APRT missense variants, c.266G>A (p.(Arg89Gln))
[10] and c. 346G>A (p.(Ala116Thr)) [28], have been
reported in individuals with decreased enzyme function that
is comparable to the heterozygous carrier state of other
pathogenic APRT variants. It is unclear if and to what extent
individuals homozygous for these variants will develop
clinical manifestations of APRT deficiency. Multiple copies
of both variants were present in the genomic databases and
the allele frequencies were quite high in both the East Asian
and South Asian populations. If proven to be disease-
causing, there could be roughly 20,000 homozygotes in
South Asia and 5000 in East Asia, assuming the Hardy-
Weinberg equilibrium. However, as no cases of APRT
deficiency caused by these two variants have been reported,
a classical phenotype appears unlikely as the disease would
then be seriously underdiagnosed. Hence, homozygosity for
these variants would either be expected to cause a very mild
clinical phenotype or no disease at all.
Of the 62 pathogenic variants, 33 were not observed in
any of the public genomic databases. Most were detected in
one or two cases except for c.188G>A (p.(Gly63Asp))
which was found in six patients, most of whom were of
Lebanese decent. The reason for this may be the high
proportion of consanguineous marriages in Lebanon, pre-
viously reported to be ~35%, and/or that Middle Eastern
populations might be underrepresented in the genomic
databases used in this study [29].
We also examined sequence variants that have not been
detected in patients with APRT deficiency in gnomAD,
which is the largest population database with the highest
allele count (Supplementary Table S7). Notably, the
c.362A>G (p.(Gln121Arg)) variant was quite common
among the African population in gnomAD, with a MAF of
0.5% and two homozygous individuals. The confirmation
of this variant or any other uncharacterized novel variants
as disease-causing in patients with APRT deficiency
would require a functional study.
The recent introduction of high-throughput sequencing
technologies and advances in bioinformatics for variant
assessment have facilitated studies of the epidemiology of
monogenic diseases. Exome sequencing has led to the dis-
covery of many novel causal genes in rare diseases [30–33].
Moreover, previously unknown pathogenic variants have
been identified and undiagnosed cases have been solved.
Creation of large public databases of human genomic
information has generated possibilities to estimate geno-
typic frequencies in various populations. Thus, the allele
frequency of rare causally-related variants can be assessed
in multiple populations like in the current study.
The prevalence of a monogenic disease depends on the
frequency of all the pathogenic variants in a population. The
allele frequency of each variant can vary in different
populations and minor alleles with much higher frequencies
than would be expected for a rare disorder should be
carefully interpreted. Correct annotation of genetic variants
is important in clinical practice as misinterpretation may
lead to incorrect diagnoses or harmful and ineffective
treatments. A limited number of variants will generally be
encountered within a given population with close to random
mating. By contrast, the occurrence of the disease in inbred
populations depends on the mating choice and each
causally-related variant can be extremely rare, sometimes
confined to a single family.
The present study has several limitations that are note-
worthy. The data collection relied largely on published
reports and is therefore probably incomplete. Although the
reports were carefully examined, there is always a possi-
bility that the cases were miscounted or missed. Further-
more, homozygous status in consanguinous unions, that are
common in certain countries, is likely to result in under-
estimation of the disease prevalence in a population under
study. It should be noted that publicly available genomic
datasets are still scarce and the inclusion of certain ethnic
groups is very limited or nonexistent. Although the gno-
mAD database contains data from various genomic projects
in the US, the American population is not identifiable in the
database so that allele frequencies cannot be assessed.
Additional work is therefore required in order to char-
acterize the prevalence of APRT deficiency around the
globe. Studies of certain ethnic groups would also be of
particular interest, for example the South Asian and African
populations. In the future, genomic information from high-
risk groups, namely patients with nephrolithiasis and/or
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unexplained chronic kidney disease presenting at a rela-
tively young age, might become publicly available. Finally,
the interpretation of previously unknown sequence variants
remains challenging and APRT enzyme activity testing
among individuals homozygous for such variants would be
of interest.
In conclusion, we identified 62 confirmed pathogenic
APRT variants, including six variants that have not been
reported previously. Three of the 62 variants account for the
majority of cases, two of which are mostly confined to
single countries, Japan and Iceland. The high carrier rate of
the missense variant p.(Asp65Val) in the Icelandic popu-
lation clearly represents a founder effect and the same
appears to hold true for the missense variant p.(Met136Thr)
in Japan. While there is no definite indication of extensive
underdiagnosis, this may nevertheless be the case in certain
areas. It is important to recognize that genomic data are still
lacking for many countries. Hence, future work should
assess the frequency of pathogenic APRT variants in
countries and populations where the number of expected
cases is higher than currently reported. An updated list of
all variants causally related to APRT deficiency will be
maintained and made publicly available on the RKSC
website.
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